Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma

INTRODUCTION: BIW-8962 is a monoclonal antibody to GM2 ganglioside that shows preclinical activity towards multiple myeloma (MM) cell lines and in animal models bearing MM xenografts. The objective of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Baz, Rachid C., Zonder, Jeffrey A., Gasparetto, Cristina, Reu, Frederic J., Strout, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315068/
https://www.ncbi.nlm.nih.gov/pubmed/28261656
http://dx.doi.org/10.1007/s40487-016-0034-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315068/
https://www.ncbi.nlm.nih.gov/pubmed/28261656
http://dx.doi.org/10.1007/s40487-016-0034-y

Ejemplares similares